Core Viewpoint - The study published in the British Medical Journal demonstrates that adding carboplatin to standard chemotherapy significantly improves survival outcomes for high-risk early-stage triple-negative breast cancer (TNBC) patients, increasing the three-year disease-free survival rate from 85.8% to 92.3% [2][3]. Study Design: Focus on High-Risk Patients - The CITRINE trial included 808 high-risk early-stage TNBC patients who underwent definitive surgical treatment, defined as high-risk due to either positive regional lymph nodes or negative lymph nodes with a Ki-67 proliferation index of ≥50% [5]. Treatment Protocol - Patients were randomly assigned to two groups: - Carboplatin group (experimental): Received four cycles of epirubicin and cyclophosphamide followed by four cycles of paclitaxel combined with carboplatin [6][7]. - Standard treatment group (control): Received four cycles of epirubicin and cyclophosphamide followed by four cycles of paclitaxel alone [9][10]. Significant Efficacy: Reduced Recurrence Risk - After a median follow-up of 44.7 months, the carboplatin group achieved a three-year disease-free survival rate of 92.3%, compared to 85.8% in the control group, indicating a 36% reduction in the risk of recurrence or death (hazard ratio of 0.64) [12][11]. Safety Profile: Manageable Risks - The incidence of grade 3-4 treatment-related adverse events was 66.7% in the carboplatin group, slightly higher than the 55.0% in the control group, primarily involving hematological toxicities. No new safety issues were identified, and there were no treatment-related deaths [15][16]. Three-Year Survival Rates - Three-year recurrence-free survival: Carboplatin group 93.8% vs. control group 88.3% - Three-year distant disease-free survival: Carboplatin group 94.8% vs. control group 89.8% - Three-year overall survival: Carboplatin group 98.0% vs. control group 94.0% [17]. Study Significance - This research fills the evidence gap regarding carboplatin in adjuvant therapy, providing a clear treatment option for high-risk TNBC patients who undergo direct surgery without neoadjuvant therapy. Over half of clinical stage II-III TNBC patients receive direct surgery, highlighting the need for effective adjuvant therapies [18]. Future Outlook: Personalized Treatment Directions - The study offers hope for high-risk early-stage TNBC patients, showing that adding carboplatin to standard chemotherapy can significantly lower recurrence risk and improve survival rates. This "Chinese solution" not only marks a milestone in breast cancer research in China but also provides new options for global TNBC treatment [20]. Future research will focus on more precise treatments through the discovery and validation of additional biomarkers, as well as the combination of carboplatin with other targeted therapies or immunotherapies [21].

Core Viewpoint - Breast cancer has become the most prevalent malignant tumor globally, and its prevention and treatment are crucial for public health. The "2025 Breast Cancer Precision Diagnosis and Long-term Survival Value Seminar" held in Shanghai focused on optimizing breast cancer diagnosis and treatment under the context of precision medicine, emphasizing patient-centered long-term survival strategies [1]. Group 1: Conference Overview - The seminar was chaired by prominent figures in the field, including Professor Shen Zhenzhou and Academician Xu Binghe, gathering top scholars to discuss the enduring value of classic treatment protocols and long-term patient management [1][3]. - The event highlighted the evolution of treatment philosophies, transitioning from "maximum tolerated" to "minimum effective" approaches, underscoring the importance of established treatment protocols as foundational elements in breast cancer care [3][5]. Group 2: Clinical Insights - Professors Shao Zhimin and Zhang Jin emphasized the clinical significance of classic drugs, advocating for deep academic exchanges to solidify consensus on their value while accelerating the development of innovative therapies [5][6]. - The discussion included the need for a dual focus on innovation and the enduring efficacy of classic treatments in enhancing patient survival and quality of life [6]. Group 3: Industry Perspectives - Dong Hao, Deputy General Manager of China Resources Pharmaceutical Group, articulated the company's commitment to integrating classic treatment strategies into clinical practice to meet unmet patient needs [8]. - The seminar also addressed the challenges and opportunities within the Chinese pharmaceutical industry, particularly in the context of drug approval reforms and the need for efficient commercialization strategies [10]. Group 4: Quality Control and Standardization - The establishment of quality control alliances and standardized treatment protocols was discussed, with a focus on enhancing regional healthcare delivery and ensuring equitable access to breast cancer care [11]. Group 5: Future Directions - The seminar concluded with a focus on the future of breast cancer treatment, emphasizing the importance of classic drugs alongside innovative therapies, particularly in the context of ongoing clinical trials and research [35][38]. - The "Net Benefit Long-term Survival Navigation Plan" was launched, aiming to improve overall management of breast cancer through collaborative efforts [31].

Core Viewpoint - The approval of the clinical trial for HDM2005 marks a significant advancement in the company's drug development process, enhancing its core competitiveness in the oncology treatment sector [1] Group 1: Clinical Trial Approval - The company's wholly-owned subsidiary, Hangzhou Sino-American East Pharmaceutical Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration for HDM2005 [1] - HDM2005 is an antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), used in combination with rituximab, cyclophosphamide, doxorubicin (or epirubicin), and prednisone (R-CHP) for treating previously untreated diffuse large B-cell lymphoma (DLBCL) [1] Group 2: Clinical Trial Progress - The drug has received approval for clinical trials in both China and the United States, with indications for advanced malignancies [1] - Currently, the drug is in the I phase of clinical trials in China, having completed the first four dose escalations without any dose-limiting toxicities (DLT), and is now in the fifth dose escalation stage [1] Group 3: Regulatory Milestones - In February 2025, HDM2005 received orphan drug designation from the FDA for the indication of mantle cell lymphoma (MCL) [1] - The approval of this clinical trial is a crucial step in the product's development, which is expected to strengthen the company's position in the oncology market [1]